3D Medicines Biopharmaceutical (Shanghai) Co., Ltd.

3D Medicines (1244.HK) is a commercial-stage oncology innovative drug development company that has independently developed multiple innovative drug candidates and vaccine products. The company has established an international professional team covering research and development, manufacturing, and commercialization, committed to helping tumor patients live longer and better. Among the company's current 17 pipelines, 8 have entered the clinical stage, and the commercial product Envida (subcutaneous injection PD-L1 single-domain antibody) has benefited tens of thousands of patients in the four years since launch, establishing a differentiated advantage in tumor immunotherapy. The company is currently driven by three independent R&D platforms, including an innovative In vivo CAR-T/NK technology platform, an AI+mRNA tumor vaccine 3D-preciseAG platform, and a radiopharmaceutical drug conjugate (RDC) R&D platform. 3D Medicines adheres to prioritizing patient benefit, and through a development strategy balancing scientific innovation and efficient commercialization, continuously enhances the global competitiveness of its products, creates long-term value for shareholders, and promotes sustainable growth in performance.